drugset / Trial / NCT01982071

A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia

NCT01982071

Phase 4 Terminated 59 enrolled Astellas Pharma Inc
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp. (Fungemia, respiratory mycosis, gastrointestinal mycosis) in adult patients in China.

Timeline

Start
2013-09-26
Primary completion
2015-08-28
Completion
2015-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Micafungin Peptide Intravenous

Indications